Daniel Wise


Daniel specialises in biologics and pharmaceuticals, with particular expertise in protein therapeutics, vaccine technology and medicinal chemistry. Much of his time is spent handling European Patent Office (EPO) opposition proceedings, in which he has extensive experience in attack and defence both at first instance and appeal. Daniel particularly enjoys representing his clients at EPO hearings and has been involved in many multiparty disputes. He supports European national patent litigations, and has coordinated EPO strategy with several pan-European litigations in the antibody and blood protein fields.  This experience has included the successful revocation of several platform patents during innovator on innovator disputes in the biologics field.

Aside from his opposition practice, Daniel carries out a range of patent work, including original drafting, prosecution at the EPO and overseas, opinions, and freedom to operate analyses. He is passionate about helping his clients to bring their innovative medicines to market, with robust protection and free of competitor patents. He has an in-depth knowledge of the complex world of supplementary protection certificates (SPCs) for authorised medicines, having coordinated several business critical SPC portfolios across the EU and advised on the infringement and validity of various third party SPCs. As the head of Carpmaels & Ransford’s SPC Group, Daniel has worked on leading SPC cases at the Court of Justice of the European Union, including the widely cited Queensland (C-630/10) and Neurim (C-130/11) referrals. He is also on the Chartered Institute of Patent Attorneys (CIPA) SPC sub-committee, which advises the UK Government on SPC matters.

Before entering the profession, Daniel studied Natural Sciences at the University of Cambridge. He specialised in biochemistry, organic chemistry and molecular biology, and carried out research into the mechanisms of platelet activation in human blood. He also spent a happy summer at Yale University investigating the genetics of protein trafficking in yeast.

“The seasoned Daniel Wise brings matchless expertise” .
IAM Patent 1000, 2018


  • MSci and MA Natural Sciences (University of Cambridge)
  • Chartered Patent Attorney
  • European Patent Attorney
  • Patent Attorney Litigator

Key Cases

  • Roxadustat – FibroGen v Three opponents (second medical uses – EPO)
  • Cubicin® – Merck v Two opponents (dosage regimens – EPO)
  • Picato® – LEO Pharma v Three opponents (formulations – EPO)